March 31, 2017 — Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was completed at New York-Presbyterian Hospital/Columbia University Medical Center in New York City. The device was used to treat a coronary bifurcation lesion involving a large side branch (appropriate for a ≥2.5mm stent) in a procedure performed by Martin Leon, M.D., director of the Center for Interventional Vascular Therapy, and Ajay Kirtane, M.D., SM, director of the Cardiac Catheterization Laboratory.
Watch a VIDEO demonstration of the deplyment for the Tryton Dedicated Bifurcation Stent.
pproximately 20-30 percent of all patients undergoing percutaneous coronary interventions (PCI) to open blocked arteries have a bifurcation lesion. The Tryton Side Branch Stent recently became the first dedicated bifurcation stent to receive regulatory approval in the United States. Tryton has signed a strategic distribution agreement with Cardinal Health enabling Cordis, its interventional vascular business, to be the exclusive distributor of the Tryton Side Branch Stent in the U.S.
The Tryton Side Branch Stent System is built using proprietary Tri-Zone technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.
Read the article "FDA Clears First Dedicated Coronary Bifurcation Stent."
For more information: www.trytonmedical.com
April 11, 2024 
